The Anxiety Disorder Treatment Market was valued at USD 12.89 billion in 2024, projected to reach USD 17.57 billion by 2032 with a CAGR of 3.95%. Increased mental health awareness and expanding therapeutic options are driving market growth. Major companies like Pfizer and Johnson & Johnson are key players in the market.

The market growth is fueled by rising mental health awareness globally, leading to increased demand for pharmacological and digital therapeutic treatments. SSRIs and SNRIs are the most prescribed treatments, with advancements in psychiatry introducing new options for long-term management. Healthcare systems are integrating telemedicine and personalized treatment models to improve access to mental healthcare.

North America leads the market with 35-37% global market share, followed by Europe with 28-30%. High awareness of mental health issues and sophisticated healthcare infrastructure contribute to North America’s dominance. Europe sees growth from government-led initiatives and increasing demand for outpatient care. Key players include Pfizer, Eli Lilly, and GlaxoSmithKline.

Recent developments include FDA approval for Johnson & Johnson’s SPRAVATO® for treatment-resistant depression and Eli Lilly’s Zepbound for obesity-related sleep apnea. Exclusive report sections cover patient demographics, treatment adoption, digital monitoring, economic burden analysis, and competitive positioning of therapy providers. SNS Insider offers market research and consulting services for clients worldwide.

Read more at GlobeNewswire: Anxiety Disorder Treatment Market Projected to Reach USD